This book deals with predominantly synthetic chemical approaches to drug design and explores the use of structure-activity relationships in the design of novel inhibitors of ribonucleotide reductase. It describes the application of the tools of structural biology to pharmaceutical development.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.